Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

515 recalls, newest first

Class II · Moderate risk

HyperLyte CR Injection

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8094-2 D-0755-2023
Class II · Moderate risk

HyperLyte CR Injection

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8094-1 D-0754-2023
Class II · Moderate risk

Lidocaine 2% HCl Inj

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8091-1 D-0753-2023
Class II · Moderate risk

Potassium Acetate Injection

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8078-1 D-0752-2023
Class II · Moderate risk

Msa 7.84% Msg 8.56%

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8029-1 D-0750-2023
Class II · Moderate risk

heparin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8100-1 D-0746-2023
Class II · Moderate risk

NORepinephrine added to dextrose 5%

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8095-1 D-0743-2023
Class II · Moderate risk

tromethamine 0.3 Molar

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8086-2 D-0741-2023

Recalls by year